


Assessing the Safety of Consumer Products by using Animal-Free Methods

Dr Julia Fentem

Head of Unilever Safety & Environmental
Assurance Centre (SEAC)

We say use science.

Not animals.



Unilever




Overview

1. My Background / Unilever Safety & Environmental Assurance Centre
2. Consumer Perspective on Animal Testing
3. Unilever Policy & Approach
4. Alternatives to Animal Testing – a short history
5. Safety Science in 2022: New Approach Methodologies (NAMs) & Next Generation Risk Assessment (NGRA) – research & application
6. Regulatory Acceptance – cosmetics, foods, chemicals
7. Closing the Science – Regulatory Use Gap
8. Looking Forwards – my thoughts on priorities

My Background

- PhD - Biochemical Toxicology
- Science Lead for a scientific animal welfare charity (FRAME, UK)
- Toxicology Section Lead for ECVAM (European Commission JRC, Italy)
- Toxicologist / Head of Product Safety (SEAC, Unilever)





Unilever – Safety & Environmental Assurance Centre (SEAC)

Ensuring Unilever’s Innovations & Products are Safe & Sustainable by Design

Safety and Environmental Science

We want consumers to be confident that our products are safe for them and their families, and better for the environment. The scientists at Unilever’s Safety and Environmental Assurance Centre (SEAC) play a key role in ensuring that our products are safe and environmentally sustainable.



Leading safety and environmental sustainability sciences

The scientists behind our safe and sustainable products



Safe and sustainable by design

How we build safety and sustainability into every product innovation.



Keeping people and the environment safe

The science-based approaches we use to keep our consumers, workers and the environment safe.



Reducing our environmental impact

How we harness the latest science to minimise our environmental footprint.

Unilever Product / Ingredient Safety Governance

- Provide scientific evidence to manage safety risks & environmental impacts

Responsible Innovation



Unilever conducts responsible sustainable research and innovation which fully respects the concerns of our consumers and society. In line with consumer needs, Unilever’s innovations are based on sound science and technology, and reflect high standards of ethical principles.

Unilever has global standards in place to ensure that all research and innovation is conducted in a safe and sustainable manner.

UNILEVER INTERNAL


Responsible Innovation Code Policy - Unilever Standard
SAFETY RISK AND ENVIRONMENTAL IMPACT ASSESSMENTS




Industry-leading Safety & Environmental Sustainability Science Capability

- Deploy expertise on higher risk business projects
- Collaborate with leading external research teams to develop & apply new capability
- Leverage our science & global networks for consumer trust & freedom to operate

Computational science is transforming our ability to do non-animal risk assessments



Informatics tools for faster data integration & decision-making



Predictive modelling for less testing & lower cost



UNIVERSITY OF CAMBRIDGE



Code of Business Principles and Code of Ethics

SEAC focuses on helping shape solutions to big scientific & societal challenges in Product Safety & Environmental Sustainability

OUR APPROACH TO SAFETY SCIENCE

ASSURING SAFETY WITHOUT THE USE OF ANIMALS

30+ Years Investment

50+ Collaborations

OUR EXPOSURE-DRIVEN, NON-ANIMAL SAFETY RISK ASSESSMENT APPROACH

EXPOSURE SCIENCE: What ingredient exposure occurs through product use?

MIEs* to PATHWAYS: Which biological processes could the ingredient stimulate or block?

What is the internal exposure to the ingredient?

Could this ingredient cause a toxic effect? If so, at what level of exposure?

Is the product exposure safe for the consumers?

Unilever

Home About TT21C Research Topics Events Resources News Working with Us Sustainability

Safety sciences in the 21st century
SCIENTIFIC RESEARCH TO UNDERPIN NEXT GENERATION RISK ASSESSMENTS

[Safety Homepage « Safety Science in the 21st Century \(tt21c.org\)](#)

OUR APPROACH TO ENVIRONMENTAL SUSTAINABILITY SCIENCE

SCIENCE TO HELP MINIMISE OUR ENVIRONMENTAL FOOTPRINT

Predictive Science

- potential future impacts of today's decisions
- innovation and sourcing of ingredients

Planetary Boundaries

- recognise that the Earth's capacity to provide resources and assimilate waste is limited.

Planetary Boundaries
A safe operating space for humanity

Credit: F. Phang/Deakin/Global

Unilever

Home About SS21C Research Topics Events Resources News Working with Us

Sustainability sciences in the 21st century
SCIENCE TO UNDERSTAND UNILEVER'S ENVIRONMENTAL FOOTPRINT

[Sustainability Homepage « Safety Science in the 21st Century \(tt21c.org\)](#)



Overview


1. My Background / Unilever Safety & Environmental Assurance Centre
- 2. Consumer Perspective on Animal Testing**
3. Unilever Policy & Approach
4. Alternatives to Animal Testing – a short history
5. Safety Science in 2022: New Approach Methodologies (NAMs) & Next Generation Risk Assessment (NGRA) – research & application
6. Regulatory Acceptance – cosmetics, foods, chemicals
7. Closing the Science – Regulatory Use Gap
8. Looking Forwards – my thoughts on priorities

Consumer Perspective on Animal Testing

MOST CONSUMERS OPPOSE ANIMAL TESTING

Only two markets – China and Japan – have a majority of consumers who support animal testing for personal care and cosmetic products. In all other markets, a majority oppose animal testing, with Mexico, France and UK having the greatest proportion of opposers.

Overall Support/Opposition of Animal Testing for Personal Care and Cosmetic Products
(Shown % Support, % Oppose)



EDELMAN Dxi | © 2019 Q5: To what extent do you support or oppose animal testing for each of the following purposes? (Shown % Top 2 Support, Bottom 2 Oppose) (Shown among Total n=16520, US n=2507, UK n=2201, China n=318, Mexico n=2284, Brazil n=2268, South Korea n=2270, Japan n=2218, France n=2254)

Top 5 Global Issues



Reducing Waste & Pollution



Reducing Plastic Packaging



Ending Animal Testing



Ingredient Transparency



Tackling Climate Change



76%

of EU adults think testing for household cleaning products should be banned

74%

of EU adults think testing for cosmetics products and their ingredients should be banned

Consumers #1 ask of global consumer products companies

United Kingdom

Reducing waste and pollution	30%
Reducing and eliminating plastic	27%
Ending animal testing	24%
Paying a fairer share of tax	24%
Tackling climate change	19%


United States

Reducing and eliminating plastic	28%
Reducing waste and pollution	25%
Ending animal testing	19%
Transparent on product ingredients	19%
Making products affordable for all	19%

Brazil


Reducing and eliminating plastic	29%
Ending animal testing	25%
Reducing waste and pollution	24%
Transparent on product ingredients	18%
Making products affordable for all	16%



Transforming safety science methods to meet consumer expectations



OUR APPROACH TO SAFETY SCIENCE

ASSURING SAFETY WITHOUT THE USE OF ANIMALS



Watch on  


Our recent video above further explains our approach and we publish more information on our scientific research on a dedicated [Safety Science in the 21st Century](#) website.

“Our leading-edge approach has one clear purpose: to continue to develop, apply and let others know about the research we do to guarantee that our products are safe, without the need for animal testing.”


Lulia Perena, Head of ISAC

For the last five years, Unilever scientists have been partnering with experts at the US Environmental Protection Agency on [collaborative research](#), to develop ground-breaking scientific approaches to better assess the safety of chemicals found in some consumer products, without using animal data.


We also work closely with researchers in the [EU ToxRisk](#) programme, which is driving changes in safety science away from animal testing. Our scientists regularly participate in discussions with regulators and scientists in China to increase the use of non-animal approaches to safety. In 2019, in recognition of our work on alternatives to animal testing we received the [Corporate Citizenship Award](#) from the Humane Society of the United States.



30+ Years Investment




50+ Collaborations



OUR EXPOSURE-DRIVEN, NON-ANIMAL SAFETY RISK ASSESSMENT APPROACH

- EXPOSURE SCIENCE** What important exposure routes brought product into contact?
- ADVERSE EFFECTS** What adverse effects should the exposure scenarios we assess?
- ADVERSE EFFECT MECHANISMS** How do the adverse effects we assess relate to the exposure scenarios we assess?
- ADVERSE EFFECT MECHANISMS** How do the adverse effects we assess relate to the exposure scenarios we assess?
- ADVERSE EFFECT MECHANISMS** How do the adverse effects we assess relate to the exposure scenarios we assess?

<https://tt21c.org/category/safety-news/>



Safety sciences in the 21st century


SCIENTIFIC RESEARCH TO UNDERPIN NEXT GENERATION RISK ASSESSMENTS

Home About TT21C Research Topics

Home | Safety News

Keyword


Presentation



On February 3, 2021

> Case studies for assuring safety without animal testing


Publication



On November 12, 2020

> Lush Science Prize 2020


Publication



On September 8, 2020

> A Next-Generation Risk Assessment Case Study for Cosmetics in Consumer Products


Presentation



On September 4, 2020

> Non-Animal Approaches to Cosmetic Safety Assessments and Applications

Presentation



On September 4, 2020

> Implementation of NAMs in a Next Generation Risk Assessment


Alternatives to animal testing

🕒 Average read time: 4 minutes


Every product Unilever makes must be safe for people to use and safe for our planet. We believe that animal experiments should not be used to make sure that our products are safe.




PBK models




HTTr - Biospyder



Cell stress



CEREP 44



- Human-relevant approaches – designed to assess the safety of ingredients
- Exposure measurements and modelling
- Computational modelling replicating human biology and chemical interactions
- Cell culture methods, using tissue grown in labs, and chemical and biological analytical techniques

Overview

1. My Background / Unilever Safety & Environmental Assurance Centre
2. Consumer Perspective on Animal Testing
- 3. Unilever Policy & Approach**
4. Alternatives to Animal Testing – a short history
5. Safety Science in 2022: New Approach Methodologies (NAMs) & Next Generation Risk Assessment (NGRA) – research & application
6. Regulatory Acceptance – cosmetics, foods, chemicals
7. Closing the Science – Regulatory Use Gap
8. Looking Forwards – my thoughts on priorities

Unilever Policy & Approach

Safe & Sustainable Products without Animal Testing

We say use science.


Not animals.



What we believe

- Every Unilever product must be safe for people and our environment
- Animal testing is not needed to assess product safety – there are a wide range of non-animal alternatives grounded in modern science and new technology

How we do it



40+ years of developing non-animal safety science






70+ collaborations



600+ publications

Unilever Policy & Brands – no animal testing



Posição da Unilever sobre Abordagens Alternativas para Testes em Animais



Não testamos nossos produtos em animais e estamos comprometidos com o banimento desses testes em nível global. Usamos uma ampla variedade de abordagens não relacionadas a animais para avaliar a segurança de nossos produtos para os consumidores, para os nossos trabalhadores e para o meio ambiente. Também desenvolvemos métodos de avaliação de segurança de "próxima geração", que não dependem de dados obtidos de animais.

Como parte de nosso compromisso de encerrar os testes em animais globalmente, um número crescente de nossas marcas garante que seus produtos e ingredientes não sejam submetidos a eles tanto por parte da Unilever, como por nossos fornecedores ou por autoridades regulatórias.

O compromisso dessas marcas é certificado por grupos globais de proteção animal. A Unilever apoia a proibição mundial de testes em animais para cosméticos até 2023.

Ocasionalmente, considerando o mais amplo e completo portfólio de marcas da Unilever, há ingredientes que ainda precisam ser testados pelos fornecedores para cumprir os requisitos legais e regulamentares em alguns mercados; e algumas autoridades governamentais testam certos produtos em animais como parte de sua legislação.



Unilever's approach: science-based safety, claims & advocacy - working with others to end animal testing of consumer products

1

Use Science, Not Animals

We use science, not animals – our industry leading capability in animal-free safety science means we do not need to use animal testing to ensure safety.

2

Independent Brand Certification

Building consumer confidence through NGO accreditation and consumer-facing no animal testing claims. Starting with Dove in 2018, we have 30 NGO-certified cruelty free brands.

3

Partnerships

Our partnerships – with global animal protection NGOs, leading research teams, other companies and government scientists – support wider acceptance and use of alternatives to animal testing.

4

Advocate for Regulatory Change

We work to end the animal testing of consumer products worldwide. We are recognised by PETA as a company working for regulatory change.

Scientific partnership & publication underpin our approach

2015



Unilever : U.S. EPA and Unilever Announce Major New Research Collaboration to Advance Non-Animal Approaches for Chemical Risk Assessment

09/08/2015 | 09:01am EDT



Research collaboration will develop ground-breaking scientific approaches to better assess the safety of chemicals found in some consumer products without using animal data



Environmental Topics ▾ Laws & Regulations ▾ Report a Violation ▾ About EPA ▾

News Releases from Headquarters > Research and Development (ORD)

CONTACT US

EPA and Unilever Announce Major Research Collaboration to Advance Non-animal Approaches for Chemical Risk Assessment

August 19, 2015

Contact Information
EPA Press Office (press@epa.gov)

WASHINGTON - Today, the U.S. Environmental Protection Agency (EPA) and Unilever announced a collaborative agreement to explore better ways to assess chemical risks associated with consumer products. This agreement builds on prior cooperation between EPA and Unilever regarding New Approach Methods (NAMs), which are a promising alternative to conventional toxicity testing that are intended to reduce reliance on the use of animals.

EPA and Unilever have been jointly evaluating and using NAMs since 2015. This collaboration is helping EPA implement its New Approach Methods Work Plan and is the foundation for new efforts to demonstrate that these novel approaches can help decision makers better protect consumers, workers and the environment.

"EPA is a pioneer in developing and applying NAMs to identify and quantify risks to human health, while reducing the use of animals in chemical toxicity testing," said H. Christopher Frey, Deputy Assistant Administrator for Science Policy in EPA's Office of Research and Development. "We are excited to continue the collaboration with Unilever, which enhances the robustness of our mutual research to demonstrate the use of NAMs."

2021

Details of SEAC's presentations & publications on www.tt21c.org

SEAC NGRA videos:

<https://www.youtube.com/watch?v=tJWG3YCXT0Y&t=10s>

<https://www.youtube.com/watch?v=5Z2S8MnKp7g>



Partnerships with over 70 leading science groups to develop & build capacity in non-animal approaches for safety assessment




Some Examples – government researchers, NGO, assay developer, supply partner

US EPA Research @EPARESEARCH · Aug 27

We're collaborating with @Unilever to advance #SaferChemicalsResearch by developing more human-relevant chemical safety tests that don't use mammals. Read the press release: [epa.gov/newsreleases/e...](https://www.epa.gov/newsreleases/e...) #NAMs

EPA and Unilever Announce Major Research Colla...
EPA News Release: EPA and Unilever Announce Major Research Collaboration to Advance Non-...
[epa.gov](https://www.epa.gov)



toxys


Toxys and Unilever enter agreement to further validate and expand ReproTracker® for animal-free developmental toxicity assessment

Toxys and Unilever will start a collaborative R&D project to further validate and develop the ReproTracker assay, a human cell assay for in vitro teratogenicity testing.


innospec

We are proud to be working together to support **SAFE USE OF INGREDIENTS** without animal testing

Advocating for change to promote regulatory use of innovative animal-free safety science & technology



The screenshot shows a news article on the Unilever website. The main headline is "Supporting a future global ban on animal testing for cosmetics". The article includes a photograph of a white rabbit being held by a person, with a syringe and a gloved hand nearby. Text on the image reads: "EUROPE STAND WITH US TO END ANIMAL TESTING #SAVECRUELTYFREECOSMETICS SAVECRUELTYFREE.EU". The article text states: "We say use science, not animals, to ensure consumer products and their ingredients are safe. Read more on our commitments, our work and the challenges." It also mentions that the European Parliament called for a global ban on animal testing for cosmetics on May 3, 2016.



The screenshot shows a webpage from OMO with the URL "https://www.omo.com/br/sem-testes-em-animais.html". The page features a large image of a young girl holding a brown rabbit. Overlaid on the image is the text "USAMOS CIÊNCIA, NÃO ANIMAIS". The article title is "OMO Testa em Animais?".

OMO TESTA EM ANIMAIS?

Não, nós usamos tecnologia e não animais para garantir que nossos produtos são seguros. Acreditamos que experimentos como esse não devem ser usados para certificar a segurança de nossos produtos

**We say use science.
Not animals.**



Overview

1. My Background / Unilever Safety & Environmental Assurance Centre
2. Unilever Policy & Approach
3. Consumer Perspective on Animal Testing
- 4. Alternatives to Animal Testing – a short history**
5. Safety Science in 2022: New Approach Methodologies (NAMs) & Next Generation Risk Assessment (NGRA) – research & application
6. Regulatory Acceptance – cosmetics, foods, chemicals
7. Closing the Science – Regulatory Use Gap
8. Looking Forwards – my thoughts on priorities

Alternatives to Animal Testing – a short history (1)

An Alternative to the LD50?

First Published March 1, 1984 | Editorial
<https://doi.org/10.1177/096032718400300201>

Article information ▾

Department Of Health And Social Security. (1982). Guidelines for the Testing of Chemicals for Toxicity on Health and Social Subjects 27. London: HMSO.

Google Scholar [To full text](#)

HOME OFFICE Report on the LD50 Test. (1979). Presented to the Secretary of State by the Advisory Committee on the Administration of Cruelty to Animals Act 1876. London.

Google Scholar [To full text](#)

> *Toxicol In Vitro*. Feb-Apr 1997;11(1-2):141-79. doi: 10.1016/s0887-2333(96)00069-0.

A summary report of the COLIPA international validation study on alternatives to the draize rabbit eye irritation test



Toxicology in Vitro

Volume 12, Issue 4, August 1998, Pages 483-524



The ECVAM International Validation Study on *In Vitro* Tests for Skin Corrosivity. 2. Results and Evaluation by the Management Team

J.H. Fentem ^{a, *}, G.E.B. Archer ^a, M. Balls ^a, P.A. Botham ^b, R.D. Curren ^c, L.K. Earl ^d, D.J. Esdale ^e, H.-G. Holzhütter ^f, M. Liebsch ^g



Toxicology in Vitro

Volume 15, Issue 1, February 2001, Pages 57-93



Validation

A prevalidation study on in vitro tests for acute skin irritation: results and evaluation by the Management Team

J.H Fentem ^{a, *}, D Briggs ^a, C Chesné ^b, G.R Elliott ^c, J.W Harbell ^d, J.R Heylings ^e, P Portes ^f, R Roguet ^f, J.J.M van de Sandt ^g, P.A Botham ^e



Guideline No. 497: Defined Approaches on Skin Sensitisation

A Defined Approach (DA) consists of a selection of information sources (e.g in silico predictions, in chemico, in vitro data) used in a specific combination, and resulting data are interpreted using a fixed data interpretation procedure (DIP) (e.g. a mathematical, rule-based model). DAs use methods in combination and are intended to overcome some limitations of the individual, stand-alone methods. The first three DAs included in this Guideline use combinations of OECD validated [▼](#) More

Published on June 22, 2021 Also available in: [French](#)

A Review of *In Silico* Tools as Alternatives to Animal Testing: Principles, Resources and Applications

Judith C. Madden, Steven J. Enoch, Alicia Paini, Mark T.D. Cronin

First Published October 29, 2020 | Review Article | [Find in PubMed](#) | [Check for updates](#)
<https://doi.org/10.1177/0261192920965977>

Adverse outcome pathways: a concise introduction for toxicologists

[Mathieu Vinken](#) [✉](#), [Dries Knapen](#), [Lucia Vergauwen](#), [Jan G. Hengstler](#), [Michelle Angrish](#) & [Maurice Whelan](#)

Archives of Toxicology **91**, 3697–3707 (2017) | [Cite this article](#)

1980s → in vitro & in silico tests for hazard identification / characterisation
2007 → toxicity pathways / adverse outcome pathways / “IATA”

Alternatives to Animal Testing – a short history (2)

Fentem, Chamberlain, Sangster. 2004. *ATLA*. 32. 617-623




Figure 2: Safety assessment — future needs
exposure-based

Safety assessment — future needs

- consumer safety decisions without animal testing
- based on scientific risk assessment
- improve relevant fundamental biological understanding
- bring experimental biology/toxicology and clinical medicine closer together (in context of human health risk assessment)
- improve *in vitro* models (tissue engineering)
- apply omics/other new technologies as appropriate
- develop *in silico* modelling tools
- move to a computational “systems biology” approach

Fentem 2006 *ATLA* 34, 11-18



2007

2021



2022



Brazil Moves Toward the Replacement of Animal Experimentation

Renato Ivan de Ávila and Marize Campos Valadares

Alternatives to Laboratory Animals
2019, Vol. 47(2), 71–81
© The Author(s) 2019
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/0261192919856806
journals.sagepub.com/home/atl
SAGE

Abstract

In Brazil, efforts towards the regulatory acceptance and implementation of innovative methods to replace experimental animal use in various fields began to gather force in 2008, with the approval of *Law No. 11,794/2008* (the Arouca Law). This law represented a milestone, as it created the National Council for the Control of Animal Experimentation (CONCEA) to deal with the ethical and legal issues related to the use of laboratory animals. In 2014, CONCEA put together a framework for expanding the implementation of non-animal methodologies for use in research and education. It also promoted the regulatory acceptance in Brazil of 24 test guidelines, including 15 *in vitro* approaches. It should be emphasised that, in Brazilian legislation, *replacement* is generally based on the toxicological endpoint and not on the category of product, as tends to be the case in other countries (e.g. cosmetics in the European Union). The resolution-dependent deadlines for the obligatory replacement of *in vivo* methods with the CONCEA-approved tests are 2019 and 2021. Brazil has advanced considerably towards the replacement of animal experimentation, and in certain aspects, this has been in a highly progressive manner. However, there is still a lot of work to be done, especially considering the current political scenario with reduced investment in research, development and innovation. The chronology of significant events following the approval of the Arouca Law, which have contributed to the promotion of the Three Rs alternatives in Brazil, will be examined.

Presidência da República Casa Civil Subchefia para Assuntos Jurídicos

LEI Nº 11.794, DE 8 DE OUTUBRO DE 2008.

Regulamenta o inciso VII do § 1º do art. 225 da Constituição Federal, estabelecendo procedimentos para o uso científico de animais; revoga a Lei nº 6.638, de 8 de maio de 1979; e dá outras providências.

2008: Law no. 11,794/2008 (Lei Arouca) represents a regulatory milestone in the implementation of alternative methods

2012: creation of RENAMA

Ministério da Ciência, Tecnologia e Inovação

GABINETE DO MINISTRO

PORTARIA Nº 491, DE 3 DE JULHO DE 2012

Institui a Rede Nacional de Métodos Alternativos - RENAMA e sua estrutura no âmbito do Ministério da Ciência, Tecnologia e Inovação - MCTI, que será supervisionada por um Conselho Diretor.

2012: ANVISA publishes guidance for cosmetics safety assessment



2014: CONCEA recognized alternative methods

Ministério da Ciência, Tecnologia e Inovação

CONSELHO NACIONAL DE CONTROLE DE EXPERIMENTAÇÃO ANIMAL

RESOLUÇÃO NORMATIVA Nº 17, DE 3 DE JULHO DE 2014

Dispõe sobre no Brasil e da

DIÁRIO OFICIAL DA UNIÃO

Publicado em: 17/01/2022 | Edição: 11 | Seção: 1 | Página: 18

Órgão: Ministério da Ciência, Tecnologia e Inovações/Conselho Nacional de Controle de Experimentação Animal

RESOLUÇÃO NORMATIVA CONCEA Nº 54, DE 10 DE JANEIRO DE 2022

Dispõe sobre o reconhecimento de métodos alternativos ao uso de animais em atividades de ensino e pesquisa científica e dá outras providências.

2015: ANVISA starts to accept the methods recognized by CONCEA



RESOLUÇÃO - RDC Nº 35, DE 7 DE AGOSTO DE 2015

Dispõe sobre a aceitação dos métodos alternativos de experimentação animal reconhecidos pelo Conselho Nacional de Controle de Experimentação Animal - Concea.

A Diretoria Colegiada da Agência Nacional de Vigilância Sanitária, no uso das atribuições que lhe conferem os incisos III e IV, do art. 15, da Lei nº 9.782, de 26 de janeiro de 1999, inciso V e §§

CONCEA currently recognizes 25 testing guidelines: 17 1R (replacement) guidelines and 8 2R (refinement & reduction) guidelines

Ministério da Ciência, Tecnologia e Inovação

GABINETE DO MINISTRO

RESOLUÇÃO NORMATIVA Nº 18, DE 24 DE SETEMBRO DE 2014

Reconhece métodos alternativos ao uso de animais em atividades de pesquisa no Brasil, nos termos da Resolução Normativa nº 17, de 03 de julho de 2014, e dá outras providências.

Ministério da Ciência, Tecnologia, Inovações e Comunicações

CONSELHO NACIONAL DE CONTROLE DE EXPERIMENTAÇÃO ANIMAL

RESOLUÇÃO NORMATIVA Nº 31, DE 18 DE AGOSTO DE 2016

Reconhece métodos alternativos ao uso de animais em atividades de pesquisa no Brasil.

DIÁRIO OFICIAL DA UNIÃO - Seção 1

CONSELHO NACIONAL DE CONTROLE DE EXPERIMENTAÇÃO ANIMAL

RESOLUÇÃO Nº 45, DE 22 DE OUTUBRO DE 2019

Reconhece método alternativo ao uso de animais em atividades de pesquisa no Brasil.



Assuring consumer safety without animal testing


- maximising use of existing information and animal-free approaches

- All our risk assessments are exposure-led



Table 2: Estimated daily exposure levels for different cosmetic product types according to Cosmetics Europe data (SCCNFP/0321/00; Hall et al., 2007, 2011).

Product type	Estimated daily amount applied	Relative amount applied (mg/kg bw/d)	Retention factor ¹	Calculated daily exposure (µg/d)	Calculated relative daily exposure (mg/kg bw/d)
Bathing, showering					
Shower gel	18.67 g	279.20	0.01	0.19	2.79
Hand wash soap ²	20.00 g	-	0.01	0.20 ³	3.33
Hair care					
Shampoo	10.46 g	150.49	0.01	0.11	1.51
Hair conditioner ²	3.92 g	-	0.01	0.04	0.60
Hair styling products	4.00 g	57.40	0.1	0.40	5.74






- Use all available safety data on the ingredient
 - clinical, epidemiological, animal (if dates permit), *in vitro*, etc.
- Exposure-based waiving approaches (e.g. toxicological threshold of concern)

- In silico* predictions
- History of safe use
- Read-across



- Use of existing OECD *in vitro* approaches
- Next Generation Risk Assessment (NGRA)**




Overview



1. My Background / Unilever Safety & Environmental Assurance Centre
2. Unilever Policy & Approach
3. Consumer Perspective on Animal Testing
4. Alternatives to Animal Testing – a short history
- 5. Safety Science in 2022: New Approach Methodologies (NAMs) & Next Generation Risk Assessment (NGRA) – research & application**
6. Regulatory Acceptance – cosmetics, foods, chemicals
7. Closing the Science – Regulatory Use Gap
8. Looking Forwards – my thoughts on priorities

Safety Science in 2022: NAMs & NGRA – research & application

NGRA is defined as an exposure-led, hypothesis-driven risk assessment approach that integrates New Approach Methodologies (NAMs) to assure safety without the use of animal testing





Applying new scientific human-relevant tools for safety decisions



Case Study – Rhamnolipid Safety Assessment

novel biosurfactant




Regulatory approach to address systemic health effects – animal testing

SEAC approach to systemic health assessment – application of next generation non-animal approaches



MODELLING



- In silico* prediction of RL membrane interaction

Number of geographies considered		
Geography	Number of geographies considered	Assessment
North America	1	Assessment
Europe	1	Assessment
Asia	1	Assessment
Latin America	1	Assessment
Africa	1	Assessment
Oceania	1	Assessment
Other	1	Assessment

- Consumer hand dish wash (HDW) habits from 15 geographies evaluated and modelled to inform *in vitro* assay design

MECHANISTIC IN VITRO ASSAYS



- Immunostimulatory potential evaluated *in vitro* and No Effect Concentration (NEC) determined
- Comparison to modelled human internal exposure – **low risk**

EXPOSURE-BASED WAIVING




- Primary route of exposure from HDW is via skin – *in vitro* skin penetration study demonstrates **no systemic exposure**
- Weight of evidence approach for metabolites – **low risk**

MECHANISTIC CHEMISTRY

Supplier *in vitro* data


Assay: [Red X] Test result: negative

OECD assay limitations: Low reactivity, Pre-hastens mixtures



- Peptide reactivity assay – components of prep bind to model peptides
- Read-across approach – **low risk**

A fundamental principle of NGRA: 'Protection not Prediction'



NGRA uses new exposure science and understanding of human biology.

The hypothesis underpinning this type of NGRA is that if there is no bioactivity observed at consumer-relevant concentrations, there can be no adverse health effects.


NGRA does not attempt to predict the results of high dose toxicology studies in animals.

A large toolbox of modern scientific methods (NAMs) is used

Not a prescriptive set of tools, but **driven by the safety assessment**

Exposure tools to inform level of systemic exposure

Bioactivity tools to provide Points of Departure






Hatherell *et al* (2020) *Toxicological Sciences*, **176**, 11-33

Moxon *et al* (2020) *Toxicology in Vitro*, **63** 104746

Li *et al* (2022) *Toxicol. Appl. Pharmacol.*, **442** 115992

Key tools (NAMs) in our NGRA approach for systemic effects

PBK Modelling



Toxicology in Vitro (2020), 63, 104746

In vitro pharmacological profiling

PERSPECTIVES

A GUIDE TO DRUG DISCOVERY — OPINION

Reducing safety-related drug attrition: the use of *in vitro* pharmacological profiling

Joanne Brown, Andrew J. Benn, Jacques Héman, Wolfgang Jorntink, Arun Sridhar, Gareth Waldron and Steven Whitbread

Abstract | *In vitro* pharmacological profiling is increasingly being used earlier in the drug discovery process to identify undesirable off-target activity profiles that could hinder or halt the development of candidate drugs or even lead to market withdrawal if discovered after a drug is approved. Here, for the first time, the rationale, strategies and methodologies for *in vitro* pharmacological profiling at four major pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Novartis and Pfizer) are presented and illustrated with examples of their impact on the drug discovery process. We hope that this will enable other companies and academic institutions to benefit from this knowledge and consider joining us in our collaborative knowledge sharing.


Decreasing the high attrition rate in the drug discovery and development process is a primary goal of the pharmaceutical industry. One of the main challenges in achieving this goal is striking an appropriate balance between drug efficacy and potential adverse effects as early as possible in order to reduce safety-related attrition, particularly in the more expensive late stages of clinical development. Gaining better understanding of the safety profile of drug candidates early in the process is also crucial for reducing the likelihood of safety issues limiting the use of approved drugs, or even leading to their market withdrawal, having to incur the immense financial and regulatory costs.

target (or targets), whose secondary effects are due to interactions with targets other than the primary target (or targets) that is off-target interactions. Off-target interactions are often the cause of ADRs in animal models or clinical studies, and so careful characterization and identification of secondary pharmacology profiles of drug candidates early in the drug discovery process might help to reduce the incidence of type A ADRs.

In vitro pharmacological profiling involves the screening of compounds against a broad range of targets (receptors, ion channels, enzymes and transporters) that are distinct from the intended

safety testing of drug candidates and are designed to prevent serious ADRs from occurring in clinical studies. The *in vitro* pharmacology assay that is absolutely required by regulatory authorities is that measures the effects of new chemical entities on the ion channels of human I_{CaL} or heterologously expressed human voltage-gated potassium channels subfamily II member 2 (hKCNH2), also known as hERG. The mechanism by which blockade of hERG can elicit potentially fatal cardiac arrhythmias (torsades de pointes) following a prolongation of the QT interval is well characterized^{1,2}, and the seriousness of this ADR is one reason why this assay is a mandatory regulatory requirement. Receptor binding studies are also recommended as the first tier approach for the assessment of the dependence potential of novel chemical entities³. However, current regulatory guidance does not describe which targets should constitute an *in vitro* pharmacological profiling panel and does not indicate the stage of the discovery process at which *in vitro* pharmacological profiling should occur. Nevertheless, the general need for more pharmaceutical companies to perform this testing early in drug discovery to reduce attrition and to facilitate better prediction of ADRs in the later stages of drug discovery and development.

Here, for the first time, four major pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Novartis and Pfizer) share their best knowledge and experience of the innovative application of existing screening technologies to detect off-target interactions of compounds. The objective of this article is to describe the rationale and main strategies for the use of *in vitro* pharmacological profiling to reduce both production and





eurolins | Cerep

Transcriptomics

- Use of full human gene panel ~ 21k
- 24 hrs exposure
- 7 concentrations
- 3 cell lines HepG2/ HepaRG/ MCF7
- 3D HepaRG spheroid



BMDexpress 2



Cellular Stress Pathways


13 chemicals, 36 Biomarkers; 3 Timepoints; 8 Concentrations; ~10 Stress Pathways

- Exposure scenario adopted for chemical is 'low risk' (from consumer goods perspective)
- Niacinamide (food, cosmetics)
 - Caffeine (beverages, cosmetics)
 - Phenoxethanol (cosmetics)
 - Sulforaphane (food)
 - tBHQ (antioxidant)
 - Triclosan (antimicrobial)
- Exposure scenario adopted for chemical is 'high risk' (from consumer goods perspective)
- CDDO-Me (drug)
 - DEM (industrial chemical)
 - Doxorubicin (drug)
 - Diclofenac (drug)
 - Troglitazone (drug)
 - Pioglitazone (drug)
 - Rosiglitazone (drug)



Toxicol Sci (2020), 176, 11-33

Unilever Next Generation Risk Assessment Framework Systemic Exposure




Hypothetical products containing coumarin




PBK models



HTTr - Biospyder



Cell stress



CERP 44




Baltazar et al., (2020) *Toxicol Sci* **176**, 236–252

A Next-Generation Risk Assessment Case Study for Coumarin in Cosmetic Products


Maria T. Baltazar,¹ Sophie Cable, Paul L. Carmichael, Richard Cubberley, Tom Cull, Mona Delagrangre, Matthew P. Dent, Sarah Hatherell, Jade Houghton, Predrag Kukic, Hequn Li, Mi-Young Lee, Sophie Malcomber, Alistair M. Middleton, Thomas E. Moxon, Alexis V. Nathanail, Beate Nicol, Ruth Pendlington, Georgia Reynolds, Joe Reynolds, Andrew White, and Carl Westmoreland

Unilever Frameworks for using NAMs to make Human Safety Decisions

Systemic




Baltazar et al (2020) *Toxicol Sci*, 176, 236-252




Inhalation

Skin Sensitisation




Reynolds et al (2021) *Reg Tox Pharmacol*, 127, 105075

Developmental & Reproductive (DART)




Rajagopal et al (2022) *Frontiers in Toxicology*, doi: 10.3389/ftox.2022.838466

Skin Allergy Risk Assessment



Entelos model

Maxwell G. & MacKay C. 2008.



SARA TKTD qAOP model

Mackay et al. 2013

T cell Forum


Kimber et al. 2012

SARA Bayesian Model

Reynolds et al. 2019

Integration of non-animal data


Jowsey et al. 2006




'Weight of Evidence' Predictions
Integration of different forms of *in vitro* and *in silico* data

Does the ingredient have the potential to 'sensitize'?


Jowsey et al. 2006




Skin Allergy AOP and SARA inputs




SARA Model Structure



SARA Human Potency





SARA Consumer Risk




Non-Animal Methods for Skin Allergy Risk Assessment (SARA)

Determining the **biological pathway** behind the adverse skin allergy reaction ...




Unilever's **SARA Model** – developed as a computational approach to integrate information from the historical data and various cell-based experiments ...

SARA Model published and collaboration with US Gov. group (NICEATM) to adapt the model for **regulatory use**.




Developing **cell-based** experiments to measure activation of different parts of the biological pathway ...



Developing a **risk assessment framework** ...



Application of NGRA Framework for Skin Allergy



Regulatory Toxicology and Pharmacology 127 (2021) 105075

Contents lists available at ScienceDirect

Regulatory Toxicology and Pharmacology

journal homepage: www.elsevier.com/locate/yrtph

A hypothetical skin sensitisation next generation risk assessment for coumarin in cosmetic products

G. Reynolds^{*}, J. Reynolds, N. Gilmour, R. Cubberley, S. Spriggs, A. Aptula, K. Przybylak, S. Windebank, G. Maxwell, M.T. Baltazar^{**}

Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire, MK44 1LQ, UK

ARTICLE INFO

Handling Editor: Dr. Lesa Aylward

Keywords and highlights:
 Skin sensitisation
 Allergic contact dermatitis
 Next generation risk assessment
 Non-animal alternatives
 New approach methodologies
 Consumer exposure
 Uncertainty analysis
 Decision making
 Metabolism

ABSTRACT

Next generation Risk Assessment (NGRA) is an exposure-led, hypothesis-driven approach which integrates new approach methodologies (NAMs) to assure safety without generating animal data. This hypothetical skin allergy risk assessment of two consumer products – face cream containing 0.1% coumarin and deodorant containing 1% coumarin – demonstrates the application of our skin allergy NGRA framework which incorporates our Skin Allergy Risk Assessment (SARA) Model. SARA uses Bayesian statistics to provide a human relevant point of departure and risk metric for a given chemical exposure based upon input data that can include both NAMs and historical *in vivo* studies. Regardless of whether NAM or *in vivo* inputs were used, the model predicted that the face cream and deodorant exposures were low and high risk respectively. Using only NAM data resulted in a minor underestimation of risk relative to *in vivo*. Coumarin is a predicted pro-hapten and consequently, when applying this mechanistic understanding to the selection of NAMs the discordance in relative risk could be minimized. This case study demonstrates how integrating a computational model and generating bespoke NAM data in a weight of evidence framework can build confidence in safety decision making.

Regulatory Toxicology and Pharmacology

Volume 131, June 2022, 105159

Next generation risk assessment for skin allergy: Decision making using new approach methodologies

N. Gilmour[✉], J. Reynolds, K. Przybylak, M. Aleksic, N. Aptula, M.T. Baltazar, R. Cubberley, R. Rajagopal, G. Reynolds, S. Spriggs, C. Thorpe, S. Windebank, G. Maxwell




Show more

+ Add to Mendeley Share Cite

<https://doi.org/10.1016/j.yrtph.2022.105159> Get rights and content

Highlights

- Application of new approach methodologies in a next generation risk assessment framework for skin allergy.
- Use of the skin allergy risk assessment (SARA) model, a defined approach for potency and risk assessment of skin sensitizers.
- Skin sensitisation risk assessment case studies using new approach methodologies.


Chemical	(±)-Lactic acid	Formaldehyde	Geraniol
CAS	50-21-5	50-00-0	106-24-1
SMILES	CC(O)C(O)=O	C=O	CC(=CCC)C(=C(CO))C(C)C
Structure			
MW (g/mol)	90.078	30.026	154.25

Inhalation Risk Assessment

Several Unilever products lead to an unintentional inhalation exposure



Historically risk assessment of ingredients in aerosols and sprays formulations relied on animal tests in rats exposed to aerosols for 28 or 90-days, 6h/day




Realistic exposure
Simulation of how consumers use our products




Realistic exposure
Simulation of particle fate in the lungs




State of the art non-animal technologies to evaluate the safety of new ingredients




Simulation of human biology in vitro



General strategy to developing an inhalation toolbox



Ongoing development of an Inhalation Framework



IVAMSS Webinar: Inhalation Toxicity: In Vitro to Human Risk Assessment
<https://www.toxicology.org/groups/ss/IVSS/Events.asp>

*Consumer Exposure in Inhalation risk assessment

Frameworks for using NAMs to make safety decisions: DART

Front Toxicol. 2022 Mar 7;4:838466. doi: 10.3389/ftox.2022.838466. eCollection 2022.

Beyond AOPs: A Mechanistic Evaluation of NAMs in DART Testing

Ramya Rajagopal¹, Maria T Baltazar¹, Paul L Carmichael¹, Matthew P Dent¹, Julia Head¹, Hequn Li¹, Iris Muller¹, Joe Reynolds¹, Kritika Sadh¹, Wendy Simpson¹, Sandrine Spriggs¹, Andrew White¹, Predrag Kucic¹

Affiliations – collapse

Affiliation

¹ Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, United Kingdom.


PMID: 35295212 PMCID: PMC8915803 DOI: 10.3389/ftox.2022.838466

[Free PMC article](#)

Abstract

New Approach Methodologies (NAMs) promise to offer a unique opportunity to enable human-relevant safety decisions to be made without the need for animal testing in the context of exposure-driven Next Generation Risk Assessment (NGRA). Protecting human health against the potential effects a chemical may have on embryo-foetal development and/or aspects of reproductive biology using NGRA is particularly challenging. These are not single endpoint or health effects and risk assessments have traditionally relied on data from Developmental and Reproductive Toxicity (DART) tests in animals. There are numerous Adverse Outcome Pathways (AOPs) that can lead to DART, which means defining and developing strict testing strategies for every AOP, to predict apical outcomes, is neither a tenable goal nor a necessity to ensure NAM-based safety assessments are fit-for-purpose. Instead, a pragmatic approach is needed that uses the available knowledge and data to ensure NAM-based exposure-led safety assessments are sufficiently protective. To this end, the mechanistic and biological coverage of existing NAMs for DART were assessed and gaps to be addressed were identified, allowing the development of an approach that relies on generating data relevant to the overall mechanisms involved in human reproduction and embryo-foetal development. Using the knowledge of cellular processes and signalling pathways underlying the key stages in reproduction and development, we have developed a broad outline of endpoints informative of DART. When the existing NAMs were compared against this outline to determine whether they provide comprehensive coverage when integrated in a framework, we found them to generally cover the reproductive and developmental processes underlying the traditionally evaluated apical endpoint studies. The application of this safety assessment framework is illustrated using an exposure-led case study.

Keywords: DART; NAMs; NGRA; mechanistic evaluation; non-animal alternatives.



Overview

1. My Background / Unilever Safety & Environmental Assurance Centre
2. Unilever Policy & Approach
3. Consumer Perspective on Animal Testing
4. Alternatives to Animal Testing – a short history
5. Safety Science in 2022: New Approach Methodologies (NAMs) & Next Generation Risk Assessment (NGRA) – research & application
- 6. Regulatory Acceptance – cosmetics, foods, chemicals**
7. Closing the Science – Regulatory Use Gap
8. Looking Forwards – my thoughts on priorities

Regulatory Acceptance – cosmetics, foods, chemicals

We are advocating for regulatory change around the world

Unilever supports calls for a global ban on animal testing for cosmetics by 2023

Product testing



Hygiene products & disinfectants



Home care products

Ingredient testing – existing ingredients



The EU's ban on animal testing for cosmetics helped change the world.
Now all that progress is at risk.

**We say use science.
Not animals.**



Ingredient testing – new ingredients



Use of animal-free approaches / NAMs for Cosmetics Safety - scientific weight-of-evidence safety risk assessments

Computational Toxicology 7 (2018) 20–26

Contents lists available at ScienceDirect

Computational Toxicology

journal homepage: www.elsevier.com/locate/comtox

Principles underpinning the use of new methodologies in the risk assessment of cosmetic ingredients

Matthew Dent^{a,*}, Renata Teixeira Amaral^b, Pedro Amores Da Silva^b, Jay Ansell^c, Fanny Boisleve^d, Masato Hatao^e, Akihiko Hirose^f, Yutaka Kasai^g, Petra Kern^h, Reinhard Kreilingⁱ, Stanley Mlstein^j, Beta Montemayor^k, Julcemara Oliveira^l, Andrea Richarz^m, Rob Taalmanⁿ, Eric Vaillancourt^o, Rajeshwar Verma^p, Nashira Vieira O'Reilly Cabral Posada^q, Craig Weiss^r, Hajime Kojima^s

^a *Children Safety and Environmental Assessment Centre, Colwell Science Park, Sharnbrook, Bedfordshire MK44 3EQ, UK*
^b *ABRISPEC - Association of the Cosmetic, Tinted and Fragrance Industry (ABRISPEC), Av. Paulista, 1513 Cosmopolis, São Paulo, SP 05311-000, Brazil*
^c *ES Personal Care Products Council (EPCPC), 1620 I St. NW, Suite 1200, Washington, D.C. 20006, USA*
^d *Johnson & Johnson Skincare Brazil Private, Av. Paulista de Magalhães, 15106-115, F 27118 1A6, 06 00222-000, São Paulo, Brazil*
^e *Japan Cosmetic Industry Association (JCIA), Moten City Kamayacho 4F, 5-1-5, Tama-ku, Minato-ku, Tokyo 105-0007 Japan*
^f *National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, 158-8501 Tokyo, Japan*
^g *Kao Corporation, External Relations & Government Affairs 2-1, Bunkyo, Setagaya-ku, Tokyo 133-8501 Japan*
^h *Procter and Gamble Services Company NV, Tomaduan 200, B-1823 Stranbeek Drievliet, Belgium*
ⁱ *German Products (DE) GmbH, Global Toxicology and Environmental, Am Dräger Park 1, 85843 Sabaiach, Germany*
^j *US Food and Drug Administration (US FDA), Office of Cosmetics and Colors (OCCAC), Center for Food Safety and Applied Nutrition (CFSA), 5001 Campus Drive, College Park, MD 20740, USA*
^k *Cosmetics Alliance Canada, 430 Brimley Road East Suite 102, Mississauga, ON L4Z 3E5, Canada*
^l *Brazilian Health Regulatory Agency (ANVISA), Gerência de Produtos de Higiene, Perfumes, Cosméticos e Saneamento, SIA Trêze de Maio 200, Área Especial 57 - CEP 71205-006, Brazil*
^m *European Commission, Joint Research Centre (JRC), Directorate for Health, Consumers and Reference Materials, Chemical Safety and Alternative Methods Unit, Via E. Fermi 2749, 21027 Segrate, VA, Italy*
ⁿ *Cosmetics Europe, Avenue Hermès-Dufour 40, 1100 Audinghem, Belgium*
^o *Health Canada (HC), Consumer Product Safety Division, Health, Environment and Consumer Safety Branch, 269 Laurier Ave. W., Ottawa, ON K1A 0R9, Canada*
^p *Independent Cosmetic Manufacturing and Distributors (ICMAD), 21925 Field Parkway, Suite 2015, Deer Park, IL 60010, USA*

ARTICLE INFO

Keywords: Next Generation Risk Assessment; New approach methodologies; Cosmetics risk assessment

ABSTRACT

Consumer safety is a prerequisite for any cosmetic product. Worldwide, there is an ever increasing desire to bring safe products to market without animal testing, which requires a new approach to consumer safety. Next Generation Risk Assessment (NGRA), defined as an exposure-led, hypothesis driven risk assessment approach that integrates *in silico*, *in chemico* and *in vitro* approaches, provides such an opportunity. The customized nature of each NGRA means that the development of a prescriptive list of tests to assess safety is not possible, or appropriate. The International Cooperation on Cosmetics Regulation (ICCR) therefore tasked a group of scientists from regulatory authorities and the Cosmetic industry to agree on and outline the principles for incorporating these new approaches into risk assessments for cosmetic ingredients. This ICCR group determined the overall goals of NGRA (to be human relevant, exposure led, hypothesis driven and designed to prevent harm); how an NGRA should be conducted (using a tiered and iterative approach, following an appropriate literature search and evaluation of the available data, and using robust and relevant methods and strategies); and how the assessment should be documented (transparent and explicit about the logic of the approach and sources of uncertainty). Those working on the risk assessment of cosmetics have a unique opportunity to lead progress in the application of novel approaches, and cosmetic risk assessors are encouraged to consider these key principles

SCCS/1628/21

Scientific Committee on Consumer Safety
SCCS

THE SCCS NOTES OF GUIDANCE FOR THE TESTING OF
COSMETIC INGREDIENTS AND THEIR SAFETY

EVALUATION
11TH REVISION

Scientific Committees
an advisory bodies
to health, environment and consumer policy

The SCCS adopted this guidance document at its plenary meeting on 30-31 March 2021

3-4 RELEVANT TOXICOLOGICAL TOOLS FOR THE SAFETY EVALUATION OF COSMETIC INGREDIENTS

The SCCS has been closely following the progress made with regard to the development and validation of alternative methods and updated its NCGI on a regular basis taking progress into consideration.

Besides validated alternatives, the SCCS may also accept, on a case-by-case basis, methods that are scientifically valid as new tools (e.g., “omics” technology) for the safety evaluation of cosmetic substances. Such valid methods may not have necessarily gone through the complete validation process, but the Committee may consider them acceptable when there is a sufficient amount of experimental data proving relevance and reliability, and including positive and negative controls.

According to the Cosmetics Regulation, the experimental studies have to be carried out in accordance with the principles of Good Laboratory Practice (GLP) laid down in Council Directive 87/18/EEC. All possible deviations from this set of rules should be explained and scientifically justified (SCCNFP/0633/02).

3-4.1 NEW APPROACH METHODOLOGY (NAM) AND NEXT-GENERATION RISK ASSESSMENT (NGRA)

Whereas the terminology of “Alternative Test Methods (ATMs)” does not cover all available tools e.g., *in silico* methodology, the more general term, New Approach Methodology (NAM) has been introduced. As for cosmetics and their ingredients, testing and marketing bans apply with respect to animal use and also the obligation exists to only use validated replacement alternatives, the need for validated non-animal alternative methods for chemical hazard assessment is much more important in Europe for compliance with the Cosmetics Regulation than for other regulatory frameworks. NAMs may include *in vitro*, *ex vivo*, *in chemico* and *in silico* methods, read-across, as well as combinations thereof. Therefore, before any testing is carried out for safety evaluation, all information on the substance under consideration should be gathered from different available means. A set of criteria, universal across initiatives, to evaluate NAMs fit-for-purpose was developed by a multi-stakeholder group and may support greater consistency across different initiatives (Parish et al., 2020).

Many efforts are ongoing to modernise toxicological safety evaluation and to look for non-animal methodology that can be used for the risk assessment of compounds that after long-term exposure could be at the origin of systemic toxicity. One of these approaches is referred to as NGRA (OECPA, 2014). The principles underpinning the application of an NGRA to cosmetics have been defined by the International Cooperation on Cosmetics Regulation (ICCR), a platform of regulators and cosmetics industry from the EU, the US, Japan, Canada and Brazil (Dent et al., 2018). NGRA is a human-relevant, exposure-led, hypothesis-driven risk assessment designed to prevent harm. It integrates several NAMs to deliver safety decisions relevant to human health without the use of experimental animals. An NGRA should be conducted using a tiered and iterative approach, following an appropriate literature search and evaluation of the available data, and using robust and relevant methods and strategies. Given the novelty of NGRA and the current lack of regulatory guidance on the use of a variety of NAMs in decision-making, it is important that the assessment should be transparently documented and explicit about the logic of the approach and sources of uncertainty (Dent et al., 2018). A general NGRA workflow is described in Figure 5 (Berggren et al., 2017). The tools useful for safety evaluation of cosmetic ingredients, which could also be used in case NGRA would be taken as a possible workflow in the future, are described in Chapters 3-4.2 to 3-4.14. Threshold of Toxicological Concern (TTC) and internal TTC (iTTC) approaches as a risk assessment tools are described in 3-5.2.

OECD
Organisation for Economic Co-operation and Development

ENV/CBC/MONO(2021)35

Unclassified English - Dr. English
27 October 2021

ENVIRONMENT DIRECTORATE
CHEMICALS AND BIOTECHNOLOGY COMMITTEE

Case Study on use of an Integrated Approach for Testing and Assessment (IATA) for Systemic Toxicity of Phenoxyethanol when included at 1% in a body lotion

Series on Testing and Assessment,
No. 349

JT03483903

This document, as well as any data and any included benefits, are without prejudice to the status of or sovereignty over any territory, to the delimitation of international frontiers and boundaries and to the name of any territory, city or area.



International Cooperation on Cosmetics Regulation (2018)



European Commission: Scientific Committee on Consumer Safety (2021)



OECD (2021)



Use of NAMs for assessing Food Safety

EFSA investing in NAMs for regulatory assessments



Finally, the development of scientific methodologies and tools, and the opportunity to refine existing ones, will offer new approaches for risk assessment in line with the 3Rs principle (Replacement, Refinement, and Reduction) to animal testing. EFSA must continue to invest in harvesting data and information to stay abreast of evolving scientific methodologies and research and develop adequate methodologies to assess new sources of potential food/feed risks such as new production technologies.

Food Safety = weight-of-evidence scientific assessments & risk control / management


Expected Operational Result 2.1.3

The quality of scientific guidance and methodologies, with the necessary risk assessment capabilities, is improved to address future challenges

KEY ACTIONS

- ▶ Ensure forward looking engagement with partners and stakeholders to achieve synergies on Risk Assessment topics of mutual interest and facilitate the development and implementation of harmonised risk assessment methodologies
- ▶ Prepare to address risk assessment challenges associated with food and feed system innovations
- ▶ Develop risk benefit approaches for chemical and biological hazards in human and environmental risk assessment
- ▶ Develop and implement systems-based approaches for regulatory environmental risk assessment
- ▶ Establish criteria and scientific assessment options to support the application of tiered approaches of methodological complexity to deliver fit for purpose assessments
- ▶ Develop and integrate new approach methodologies (NAMs) and omics for regulatory risk assessment
- ▶ Develop risk assessment of combined exposure to multiple chemicals, across regulatory domains
- ▶ Integrate, bioinformatic and cheminformatics approaches, technologies and data into next generation risk assessment
- ▶ Consider how microbiomes could be included in risk assessment, and develop tools to enable this
- ▶ Keep EFSA's risk assessment processes updated in line with evolving regulatory, policy and quality drivers (TR)

Uptake of NAMs for assessing Chemical Safety being led by US EPA



APCRA
ACCELERATING THE PACE OF CHEMICAL RISK ASSESSMENT

SOT Society of Toxicology
academic.oup.com/toxsci

Tox Spotlight

TOXICOLOGICAL SCIENCES, 173(1), 2020, 202-225
doi: 10.1093/toxsci/kfz011
Advance Access Publication Date: September 18, 2019
Research Article

Utility of *In Vitro* Bioactivity as a Lower Bound Estimate of *In Vivo* Adverse Effect Levels and in Risk-Based Prioritization

Katie Paul Friedman, ^{1,2,3} Matthew Gagne, ¹ Lit-Hsin Loo, ² Panagiotis Karamertzanis, ⁵ Tatiana Netzeva, ⁵ Tomasz Sobanski, ⁵ Jill A. Franzosa, ⁶ Ann M. Richard, ⁷ Ryan R. Lougee, ¹¹ Andrea Gissi, ⁵ Jia-Ying Joey Lee, ⁵ Michelle Angrish, ¹¹ Jean Lou Dorne, ¹¹ Steven Foster, ⁸ Kathleen Raffaele, ⁸ Tina Bahadori, ⁹ Maureen R. Gwinn, ⁹ Jason Lambert, ⁹ Maurice Whelan, ¹⁰ Mike Rasenberg, ⁵ Tara Barton-Maclaren, ¹ and Russell S. Thomas ¹²

"The primary objective of this work was to compare PODs based on high-throughput predictions of bioactivity, exposure predictions, and traditional hazard information for 448 chemicals"

The figure is a scatter plot with 'log10 mg/kg bw/day' on the x-axis (ranging from -4 to 2) and 'POD' on the y-axis. It shows a dense distribution of data points for 448 chemicals, with red horizontal bars indicating specific POD levels.



NAMs and REACH / EU Chemicals Strategy for Sustainability

Re-thinking the EU's approach to chemical safety

- Whilst NAMs are increasingly used for safety assessment purposes, their application in chemicals registration remains limited
- New animal testing requested for widely used existing chemicals under REACH
- Failure of ECHA to implement 'animal testing as a last resort'
- Inconsistency in EU approaches for establishing product and ingredient (chemical) safety

Comment

Upholding the EU's Commitment to 'Animal Testing as a Last Resort' Under REACH Requires a Paradigm Shift in How We Assess Chemical Safety to Close the Gap Between Regulatory Testing and Modern Safety Science

Alternatives to Laboratory Animals
2021, Vol. 0(0) 1-11
© The Author(s) 2021

Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/02611923211040824
journals.sagepub.com/home/atl


Julia Fentem, Ian Malcomber, Gavin Maxwell and Carl Westmoreland

Abstract

Animal use for testing chemicals under REACH continues to increase, despite advances in non-animal safety science during the past 15 years. The application of modern science and technology, and the use of 'next generation' weight-of-evidence assessment approaches, are embedded in EU guidance for establishing the safety of cosmetics and foods – and of the ingredients used in these products. However, this is still not the case for the regulation of chemicals. Under the new Chemicals Strategy for Sustainability, thought leaders in human health and environmental protection are calling on the European Commission to quickly embrace the benefits of modern and innovative non-animal safety science, in place of outdated animal testing, if the EU is to be a leader in safe and sustainable innovation under the European Green Deal transformational change ambitions. The European Commission also needs to enable companies to meet their legal obligation to only conduct animal testing as a last resort, by providing a more flexible, science-based and consistent regulatory framework for assuring chemical safety, which supports the integration of data from different sources. We are at a tipping point for closing the gap between regulatory chemicals testing and modern safety science. It is time to join forces, across policy makers, scientists, regulators and lawyers, to lead the paradigm shift needed to deliver what EU citizens want – namely, chemicals and products that are safe and sustainable, without resorting to animal testing.

We call on the European Commission to do the following:

1. Protect and strengthen the cosmetics animal testing ban.

Initiate legislative change to achieve consumer, worker, and environmental protection for all cosmetics ingredients without testing on animals for any purpose at any time.

2. Transform EU chemicals regulation.

Ensure human health and the environment are protected by managing chemicals without the addition of new animal testing requirements.

3. Modernise science in the EU.

Commit to a legislative proposal plotting a roadmap to phase-out all animal testing in the EU before the end of the current legislative term.



European Citizens' Initiative

Overview

1. My Background / Unilever Safety & Environmental Assurance Centre
2. Unilever Policy & Approach
3. Consumer Perspective on Animal Testing
4. Alternatives to Animal Testing – a short history
5. Safety Science in 2022: New Approach Methodologies (NAMs) & Next Generation Risk Assessment (NGRA) – research & application
6. Regulatory Acceptance – cosmetics, foods, chemicals
- 7. Closing the Science – Regulatory Use Gap**
8. Looking Forwards – my thoughts on priorities

Closing the Science – Regulatory Use Gap

Safety scientists are calling for paradigm shift & regulatory change
- safe & sustainable ingredients without animal testing

Comment

Upholding the EU's Commitment to 'Animal Testing as a Last Resort' Under REACH Requires a Paradigm Shift in How We Assess Chemical Safety to Close the Gap Between Regulatory Testing and Modern Safety Science

Julia Fentem, Ian Malcomber, Gavin Maxwell and Carl Westmoreland

Alternatives to Laboratory Animals
2021, Vol. 49(4) 123–132
© The Author(s) 2021
SAGE
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/02611929211040824
journals.sagepub.com/home/alx
SAGE


Archives of Toxicology
<https://doi.org/10.1007/s00204-021-03215-9>

REGULATORY TOXICOLOGY

A framework for chemical safety assessment incorporating new approach methodologies within REACH

Nicholas Ball¹ · Remi Bars² · Phillip A. Botham³ · Andreea Cuclureanu⁴ · Mark T. D. Cronin⁵ · John E. Doe⁵ · Tatsiana Dudzina⁶ · Timothy W. Gant⁷ · Marcel Leist⁸ · Bennard van Ravenzwaay⁹


Received: 11 October 2021 / Accepted: 21 December 2021
© The Author(s) 2022



Time to re-think & modernise our approach ...

1. Conducting an animal test because it's a (perceived) regulatory requirement isn't adequate scientific justification
2. Current laws and regulations, not science, are impeding the paradigm shift to using modern animal-free safety science
3. Change regulatory approach to chemical safety to strengthen the protection of people (workers & consumers) and our environment, without that being anchored in predicting the apical toxicity effects seen in high-dose animal studies

Using advanced science to assess chemical (ingredient) safety - action needed to modernise chemicals regulatory frameworks



Scientifically justify
'animal testing
as a last resort'
+
Paradigm shift in
how we assess
ingredient safety



Regulatory
compliance
=
**Best science
to protect
people & our
environment**



get creative using relevant
NAMs* / scientific data



modernise Legal &
Regulatory requirements



develop NAM-based
regulatory frameworks

*NAM = New Approach Methodology

Comment

Upholding the EU's Commitment to 'Animal Testing as a Last Resort' Under REACH Requires a Paradigm Shift in How We Assess Chemical Safety to Close the Gap Between Regulatory Testing and Modern Safety Science


Alternatives to Laboratory Animals
2021, Vol. 000 1-11
© The Author(s) 2021

Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/02611929211040824
journals.sagepub.com/home/at
SAGE

Julia Fentem, Ian Malcomber, Gavin Maxwell and Carl Westmoreland

Law—Not Science—Impedes Shift to Non—Animal Safety Testing

June 18, 2021, 9:01 AM



Testing products on animals is slowly ending, but there are still some obstacles to completely ending the practice, explains Gary E. Marchant, a professor at the Sandra Day O'Connor College of Law at Arizona State University. He discusses three impediments, including legal barriers from federal regulatory agencies.



Gary Marchant

Sandra Day O'Connor College of Law

Cosmetics
design-europe.com

THE LONG READ: IN CONVERSATION WITH UNILEVER SAFETY & ENVIRONMENTAL ASSURANCE CENTRE (SEAC) EXECUTIVES

The future of animal-free chemical testing? There's a 'big frustration' in the scientific community, say Unilever execs

By Kacey Culliney

20-Oct-2021 - Last updated on 20-Oct-2021 at 09:54 GMT

Overview

1. My Background / Unilever Safety & Environmental Assurance Centre
2. Unilever Policy & Approach
3. Consumer Perspective on Animal Testing
4. Alternatives to Animal Testing – a short history
5. Safety Science in 2022: New Approach Methodologies (NAMs) & Next Generation Risk Assessment (NGRA) – research & application
6. Regulatory Acceptance – cosmetics, foods, chemicals
7. Closing the Science – Regulatory Use Gap
- 8. Looking Forwards – my thoughts on priorities**

Looking Forwards – my thoughts on priorities


“Close the Investigative – Regulatory Toxicology Gap”

→ demonstrate how modern safety science & our new toolbox can lead to decisions which better protect human health & our environment

1. develop a **modern, science-based, chemicals regulatory framework**, which facilitates use of 21C science & technology to better protect people and the environment – **regulatory change**
2. establish open dialogue on, and **transparent scientific evaluation** of, NAM strategies for specific chemicals / chemical groups – **case studies**
3. accelerate **knowledge transfer & training** in advanced safety science and NAM-based chemical assessments - **regulators / industry**
4. stimulate **capacity building in NAMs** to increase the number of service providers of new “NAMs toolbox” – **research & innovation**

We say use science.
Not animals.

#UseScienceNotAnimals



Accelerating Knowledge Transfer to Build Capability & Capacity

AFSA
ANIMAL-FREE SAFETY ASSESSMENT COLLABORATION

HOME WHY ANIMAL-FREE COSMETICS BIOLOGICALS CHEMICALS EVENTS

TRAINING & EDUCATION WEBINARS

Registration now open!

Events - AFSA (afsacollaboration.org)

ZOOM WEBINAR

Tues. May 10
11:00 – 12:30 GMT

GLOBAL REGULATORY LANDSCAPE

Global Regulatory Landscape

Zoom 10th May 2022

ZOOM WEBINAR

Thurs. May 5
13:00 – 14:30 GMT

DOSIMETRY

Internal exposure and IVIVE

Presented by AFSA Collaboration members:
Rebecca Clewell, 21st Century Tox Consulting

Dosimetry: Internal Exposure & IVIVE

Zoom 5th May 2022

ZOOM WEBINAR

Tues. April 26
11:00 – 12:30 GMT

PREDICTIVE CHEMISTRY

In silico tools and read-across

Predictive Chemistry: In silico tools and read-across

Zoom 26th April 2022

ZOOM WEBINAR

Thurs. April 14
13:00 – 14:30 GMT

CONSUMER EXPOSURE

Presented by AFSA Collaboration members:

Consumer Exposure

Zoom 14th April 2022

Capacity building: Education and Training Program in Animal-Free Safety Assessment of Chemicals - AFSA (afsacollaboration.org)

Top performer! 🏆

AFSA Animal-Free Safety Assessment Collaboration
2,810 followers

A special THANK YOU to all our wonderful partners! We are grateful for your expertise and assistance in launching our new training program which aims to promote a better, kinder approach to safety!

Unilever / L'Oréal / Firmenich / Procter & Gamble / Givaudan / Avon / International Flavors & Fragrances / Humane Society International / Symrise AG / Institute for In Vitro Sciences, Inc. / Lhasa Limited / Delphic HSE / Lush Fresh Handmade Cosmetics North America

Stay tuned – details about our four new webinars coming on Friday, March 18! And to learn more about the AFSA Collaboration visit: afsacollaboration.org/

#TrainingProgram #Partnership #AnimalFreeSafety #UseScienceNotAnimals #BeCrueltyFree

AFSA COLLABORATION

Unilever L'ORÉAL
Firmenich
P&G Givaudan
AVON iff
HUMANE SOCIETY INTERNATIONAL
symrise
IVIS Institute for In Vitro Sciences Lhasa Limited
Delphic HSE LUSH

A huge thank you to all our Cosmetics Training & Education Partners!

To learn more visit: afsacollaboration.org

AFSA Animal-Free Safety Assessment Collaboration
2,810 followers

To complement legislative efforts to end cosmetic animal testing, we are developing training materials to build capacity in the application of animal-free risk assessment of cosmetics and ingredients. This will support the development of new and safer products as well as robust safety decisions.

To learn more about our Training & Education program visit: <https://lnkd.in/d/GWFFHGP>

Stay tuned - webinar details coming on Friday!

#AnimalFreeSafety #UseScienceNotAnimals #BetterScience #BeCrueltyFree




AFSA COLLABORATION

We're excited to announce our new Training Program!

To learn more visit: afsacollaboration.org

Building Confidence in using NAMs for Regulatory Purposes

Evaluating the NAMs toolbox for consumer safety decision-making



OXFORD UNIVERSITY PRESS | Toxicological Sciences

Are non-animal systemic safety assessments protective? A toolbox and evaluation strategy

- Data Generation
- Case Studies
- Scientific Evaluation
- Publication

Regulatory Toxicology and Pharmacology 131 (2022) 105159

Contents lists available at ScienceDirect

Regulatory Toxicology and Pharmacology

journal homepage: www.elsevier.com/locate/yrtp

Next generation risk assessment for skin allergy: Decision making using new approach methodologies

N. Gilmour*, J. Reynolds, K. Przybylak, M. Aleksic, N. Aptula, M.T. Baltazar, R. Cubberley, R. Rajagopal, G. Reynolds, S. Spriggs, C. Thorpe, S. Windebank, G. Maxwell

Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire, MK44 1LQ, UK

These case study outcomes suggest that NGRA based upon NAM and SARA model predictions are at least as protective as the historical risk assessment approaches. Through case studies such as those presented here, we are building our confidence in utilising NAM data in risk assessments for skin allergy and making decisions on consumer safety based upon the weight of all available evidence. These initial case studies represent relatively simple decisions based upon use of NAM data, additional case studies and further evaluation of the NGRA framework for skin sensitisation are required.



Acknowledgements

thank you to SEAC's science leads / teams & our external partners

Carl Westmoreland

Gavin Maxwell

Renato Ivan de Ávila

Maria Baltazar

Paul Carmichael

Stella Cochrane

Claire Davies

Matt Dent

Nicola Gilmour

Predrag Kukic

Hequn Li

Alistair Middleton

Iris Müller

Ramya Rajagopal

Georgia Reynolds



Congratulations to ReNaMA on your 10th anniversary



**We say use science.
Not animals.**



& many SEAC colleagues

